CYTK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cytokinetics Inc (CYTK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including FDA approval for MYQORZO, promising analyst ratings, and a high potential for growth in the hypertrophic cardiomyopathy market. Despite short-term losses, the company's long-term growth outlook and recent developments make it a solid choice for long-term investment.
The stock's technical indicators show mixed signals. The MACD is negative and expanding, indicating bearish momentum, while the RSI is neutral at 32.299. However, the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an upward trend in the long term. The key support level is $62.268, and the current price is near this level, making it a potentially favorable entry point.
FDA approval for MYQORZO for symptomatic obstructive HCM and its recent launch in the U.S.
Strong analyst ratings with multiple price target increases, some as high as $
Promising upcoming Phase 3 ACACIA trial results for non-obstructive HCM in Q2
Revenue growth of 4.89% YoY in Q4 2025, indicating progress despite challenges.
Hedge funds are selling, with a significant increase in selling activity (5964.05% over the last quarter).
The company reported a net loss of $183 million in Q4 2025, with projected high expenses for 2026 ($830M-$870M).
MACD indicates bearish momentum in the short term.
In Q4 2025, Cytokinetics reported revenue growth of 4.89% YoY to $17.75 million. Net income improved by 22% YoY but remains negative at -$183 million. EPS also improved by 17.32% YoY to -$1.49. Gross margin remains strong at 100%. Despite losses, the company is investing heavily in growth, including clinical trials and market expansion.
Analysts are overwhelmingly positive on CYTK, with multiple Buy and Outperform ratings. Price targets range from $66 to $108, with a consensus around $90-$100. Analysts highlight the strong potential of MYQORZO and upcoming clinical trial results as key drivers for future growth.
